PhRMA welcomes Russia's progress toward WTO accession, but has reservations on IP

14 November 2011

The Working Party on Russia’s Accession to the World Trade Organization (WTO) in Geneva said last week that an agreement on Russian accession has been reached: Membership for the largest nation outside the 153-member WTO will now be put to a vote at a December 15-17 meeting of trade ministers in Geneva.

Russia's entry will be the biggest step in global trade liberalization since China joined a decade ago, and will boost the country's $1.5 trillion economy, according to the World Bank.

“Russia's membership in the WTO will lower tariffs, improve international access to Russia's services markets, hold the Russian government accountable to a system of rules governing trade behavior, and provide the means to enforce those rules,” US President Barack Obama said of the news, quoted by Bloomberg.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical